Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEB1102 in Arginase I Deficiency
NCT02488044Phase 2Completed
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Jun 2016
- Primary completion
- Feb 2019
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of pegzilarginase in arginase I deficiency (ARG1-D), sponsored by Spyre Therapeutics, Inc.. Started Jun 2016; status: completed.
02
Drugs
pegzilarginase
03
Conditions
arginase I deficiency (ARG1-D)
Beyond the preview
Go deeper on NCT02488044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488044.